Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting120%
completed480%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

NCT05765825
completedphase_2

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NCT05386888
completedphase_2

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

NCT03631784
completedphase_2

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

NCT04622228
completedphase_3

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959

Clinical Trials (5)

Showing 5 of 5 trials
NCT05765825Phase 2

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Active Not Recruiting
NCT05386888Phase 2

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Completed
NCT03631784Phase 2

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Completed
NCT04622228Phase 2

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Completed
NCT00686959Phase 3

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5